Electromed Downgraded by StockNews.com While Other Ratings Shift

Investment analysts at StockNews.com have recently adjusted their rating on shares of Electromed (NYSE:ELMD) from 'strong-buy' to 'buy'. The update to Electromed's stock rating was issued in their latest research note on Friday, indicating a shift in their outlook on the company's investment potential.

Electromed's Review by TheStreet

In a separate evaluation, TheStreet has also revised their rating for Electromed, moving from a 'b-' down to a 'c+' on Monday, July 31st. These changes in ratings reflect a re-assessment of Electromed's financial health and market performance by research analysts.

Electromed's Market Performance

Electromed's stock began trading at $10.25 on Friday, with the company's share value fluctuating between a 12-month low of $8.80 and a high of $13.84. Its 50-day and 200-day simple moving averages stood at $10.46 and $10.92, respectively. The firm's market capitalization is approximately $87.95 million, with a price-to-earnings ratio of 27.70 and a beta value of 0.40.

Recent Earnings and Institutional Involvement

For the quarter ending Tuesday, August 22nd, Electromed reported earnings per share (EPS) of $0.12, which surpassed the consensus estimate by $0.02. This is indicative of an 8.78% return on equity and a net margin of 6.51%. During the same quarter, the company also posted $13.61 million in revenue.

Noteworthy institutional movements include Dimensional Fund Advisors LP increasing their holdings by 1.5%, State Street Corporation (NYSE:STT) augmenting their stake by 23.3%, and Royal Bank of Canada (TSX:RBCPF) raising their stake by 4.1%. Vanguard Group Inc. and Cetera Advisor Networks LLC were also among the institutions adjusting their investments in Electromed.

About Electromed

Operating both domestically and internationally, Electromed, Inc., specializes in the development, manufacturing, marketing, and sale of airway clearance therapy products, using high frequency chest wall oscillation (HFCWO) for patients with compromised pulmonary functions. Their product line includes the SmartVest and SmartVest Connect systems.

Electromed, StockNews, TheStreet, Rating, Downgrade, Analysts, Shares, Investment, Market, Performance, Earnings, Institutional, Investors, StateStreet, RoyalBank